Nuveen Asset Management LLC Lowers Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Nuveen Asset Management LLC decreased its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 5.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 434,058 shares of the company's stock after selling 25,474 shares during the period. Nuveen Asset Management LLC owned about 0.51% of Syndax Pharmaceuticals worth $5,738,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in SNDX. Granahan Investment Management LLC raised its position in Syndax Pharmaceuticals by 36.2% during the fourth quarter. Granahan Investment Management LLC now owns 905,322 shares of the company's stock worth $11,968,000 after acquiring an additional 240,557 shares during the period. Octagon Capital Advisors LP acquired a new position in shares of Syndax Pharmaceuticals during the 4th quarter worth about $11,951,000. Northern Trust Corp lifted its stake in Syndax Pharmaceuticals by 7.5% in the 4th quarter. Northern Trust Corp now owns 792,750 shares of the company's stock valued at $10,480,000 after buying an additional 55,144 shares in the last quarter. Algert Global LLC lifted its stake in Syndax Pharmaceuticals by 65.4% in the 4th quarter. Algert Global LLC now owns 785,632 shares of the company's stock valued at $10,386,000 after buying an additional 310,634 shares in the last quarter. Finally, Crestline Management LP boosted its holdings in Syndax Pharmaceuticals by 66.4% in the 4th quarter. Crestline Management LP now owns 713,205 shares of the company's stock worth $9,429,000 after buying an additional 284,667 shares during the last quarter.

Analysts Set New Price Targets

SNDX has been the topic of several research reports. Wall Street Zen upgraded Syndax Pharmaceuticals to a "sell" rating in a research report on Tuesday, May 6th. HC Wainwright restated a "buy" rating and issued a $51.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. Guggenheim reaffirmed a "buy" rating and set a $32.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 6th. Scotiabank increased their target price on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a "sector perform" rating in a research report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an "overweight" rating in a research report on Thursday, March 20th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $35.91.

Syndax Pharmaceuticals Trading Up 4.2%

SNDX stock traded up $0.44 during trading on Monday, reaching $10.98. 3,025,442 shares of the stock were exchanged, compared to its average volume of 1,790,749. The firm has a market capitalization of $944.80 million, a price-to-earnings ratio of -3.02 and a beta of 0.82. The business has a 50 day moving average price of $11.49 and a 200-day moving average price of $13.39. Syndax Pharmaceuticals, Inc. has a 1 year low of $8.58 and a 1 year high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.06. The firm had revenue of $20.04 million for the quarter, compared to analysts' expectations of $15.88 million. The firm's quarterly revenue was up 1900.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.85) EPS. On average, research analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).